药品详细

Rabeprazole(雷贝拉唑)

基本信息
剂型规格
适应症
药理
临床
理化性质
相互作用
文档
专利
Pathway
文献
序列

化学结构式图

中文名

雷贝拉唑

英文名

Rabeprazole

分子式

C₁₈H₂₁N₃O₃S

化学名

2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methane}sulfinyl)-1H-1,3-benzodiazole

分子量

Average: 359.443
Monoisotopic: 359.130362243

CAS号

117976-89-3

ATC分类

A02B 未知

药物类型

small molecule

阶段

approved

商品名

AcipHex;Pariet;

同义名

Irsogladine Maleate;rabeprazole sodium;Rebeprazole sodium;

基本介绍

Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug – in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion.

生产厂家

Eisai Corporation
Eisai inc
Teva pharmaceuticals usa inc

封装厂家

参考

Synthesis Reference	Not Available
General Reference	Not Available

剂型

规格

化合物类型

Type	small molecule

Classes

Benzimidazoles
Ethers

Substructures

Benzimidazoles
Pyridines and Derivatives
Ethers
Benzene and Derivatives
Imidazoles
Heterocyclic compounds
Aromatic compounds
Imines
Cyanamides
Sulfoxides

适应症

gastric acid RELATED DISORDERS 中和胃酸;

药理

Indication

For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.

Pharmacodynamics

Rabeprazole prevents the production of acid in the stomach. It reduces symptoms and prevents injury to the esophagus or stomach in patients with gastroesophageal reflux disease (GERD) or ulcers. Rabeprazole is also useful in conditions that produce too much stomach acid such as Zollinger-Ellison syndrome. Rabeprazole may also be used with antibiotics to get rid of bacteria that are associated with some ulcers. Rabeprazole is a selective and irreversible proton pump inhibitor, suppresses gastric acid secretion by specific inhibition of the H⁺, K⁺ -ATPase, which is found at the secretory surface of parietal cells. In doing so, it inhibits the final transport of hydrogen ions (via exchange with potassium ions) into the gastric lumen.

Mechanism of action

Rabeprazole belongs to a class of antisecretory compounds (substituted benzimidazole proton-pump inhibitors) that do not exhibit anticholinergic or histamine H2-receptor antagonist properties, but suppress gastric acid secretion by inhibiting the gastric H⁺/K⁺ATPase (hydrogen-potassium adenosine triphosphatase) at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, rabeprazole has been characterized as a gastric proton-pump inhibitor. Rabeprazole blocks the final step of gastric acid secretion. In gastric parietal cells, rabeprazole is protonated, accumulates, and is transformed to an active sulfenamide. When studied in vitro, rabeprazole is chemically activated at pH 1.2 with a half-life of 78 seconds.

Absorption

Absolute bioavailability is approximately 52%.

Volume of distribution

Not Available

Protein binding

96.3% (bound to human plasma proteins)

Metabolism

Hepatic

Route of elimination

Following a single 20 mg oral dose of 14C-labeled rabeprazole, approximately 90% of the drug was eliminated in the urine, primarily as thioether carboxylic acid; its glucuronide, and mercapturic acid metabolites.

Half life

1-2 hours (in plasma)

Clearance

Not Available

Toxicity

Not Available

Affected organisms

Humans and other mammals

Pathways

Pathway	Name	SMPDB ID
	Rabeprazole Pathway	SMP00229

理化性质

Properties

State

solid

Experimental Properties

Property	Value	Source
logP	0.6	Not Available

Predicted Properties

Property	Value	Source
water solubility	3.36e-01 g/l	ALOGPS
logP	2.04	ALOGPS
logP	2.09	ChemAxon
logS	-3	ALOGPS
pKa (strongest acidic)	9.35	ChemAxon
pKa (strongest basic)	4.24	ChemAxon
physiological charge	0	ChemAxon
hydrogen acceptor count	5	ChemAxon
hydrogen donor count	1	ChemAxon
polar surface area	77.1	ChemAxon
rotatable bond count	8	ChemAxon
refractivity	98.07	ChemAxon
polarizability	39.64	ChemAxon

药物相互作用

Drug	Interaction
Atazanavir	Rabeprazole may decrease the serum levels and therapeutic effects of atazanavir.
Cefditoren	Proton pump inhibitors such as rabeprazole may decrease the serum concentration of cefditoren. If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided.
Clopidogrel	Rabeprazole may decrease serum concentrations of the active metabolite(s) of clopidogrel. Due to the possible risk for impaired clopidogrel effectiveness with this combination, clinicians should carefully consider the need for concurrent rabeprazole therapy in patients receiving clopidogrel. Monitor response to clopidogrel closely when using clopidogrel with rabeprazole. Whether there are differences among individual proton pump inhibitors is unclear. Other acid-lowering therapies (e.g., H2-receptor antagonists, antacids, etc.) do not appear to share this interaction with clopidogrel.
Dasatinib	Rabeprazole may decrease the serum level of dasatinib.
Digoxin	Rabeprazole increases the effect of digoxin
Enoxacin	Rabeprazole may decrease the absorption of enoxacin.
Indinavir	Omeprazole decreases the absorption of indinavir
Itraconazole	The proton pump inhibitor, rabeprazole, may decrease the absorption of itraconazole.
Ketoconazole	The proton pump inhibitor, rabeprazole, may decrease the absorption of ketoconazole.
Rilpivirine	Proton-pump inhibitors increase gastric pH which causes a decrease in the exposure of rilpivirine thus reducing efficacy.
Tretinoin	The moderate CYP2C8 inhibitor, Rabaprazole, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Rabaprazole is initiated, discontinued to dose changed.

食物相互作用

Take without regard to meals.
Take without regard to meals. Food may slow absorption rate but extent of absorption is not affected.

返回 | 收藏